503B Outsourcing Facility

A 503B outsourcing facility is a compounding facility registered with the FDA that can produce larger batches of compounded drugs without patient-specific prescriptions — the key difference from traditional 503A compounding pharmacies. Under Section 503B of the FD&C Act, these facilities operate under stricter oversight than 503A pharmacies: current Good Manufacturing Practice (cGMP) requirements, FDA inspection, and stricter labelling and reporting standards. In exchange, they can sell compounded drugs to healthcare facilities in bulk. 503B facilities cannot compound drugs that are essentially copies of FDA-approved products with active NDAs, just like 503A pharmacies. But they can provide hospital formularies and clinics with compounded alternatives to drugs that are commercially unavailable or in shortage. For peptides, the 503B pathway is less common than 503A because the patient-specific prescription model is typical for research peptide prescribing. 503B facilities are more relevant for hospital-use compounded medications (like injectable pain management compounds) than for the outpatient peptide context. The PCAC review process affects bulk substance eligibility for 503A pharmacies; 503B facilities have a separate nominated substances pathway.